
Federico Da Settimo Passetti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6174966/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	¹¹ C-ER176, a Radioligand for 18-kDa Translocator Protein, Has Adequate Sensitivity to Robustly Image All Three Affinity Genotypes in Human Brain. Journal of Nuclear Medicine, 2017, 58, 320-325.	5.0	146
2	Arylthioamides as H ₂ S Donors: <scp>I</scp> -Cysteine-Activated Releasing Properties and Vascular Effects in Vitro and in Vivo. ACS Medicinal Chemistry Letters, 2013, 4, 904-908.	2.8	144
3	Pyrido[1,2- <i>a</i>]pyrimidin-4-one Derivatives as a Novel Class of Selective Aldose Reductase Inhibitors Exhibiting Antioxidant Activity. Journal of Medicinal Chemistry, 2007, 50, 4917-4927.	6.4	130
4	Adenosine Deaminase in the Modulation of Immune System and its Potential as a Novel Target for Treatment of Inflammatory Disorders. Current Drug Targets, 2012, 13, 842-862.	2.1	128
5	Recent Advances in the Development of Dual Topoisomerase I and II Inhibitors as Anticancer Drugs. Current Medicinal Chemistry, 2010, 17, 4270-4290.	2.4	125
6	Sampling protein motion and solvent effect during ligand binding. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 1467-1472.	7.1	100
7	Inhibition of Adenosine Deaminase Attenuates Inflammation in Experimental Colitis. Journal of Pharmacology and Experimental Therapeutics, 2007, 322, 435-442.	2.5	96
8	Identification of 5-arylidene-4-thiazolidinone derivatives endowed with dual activity as aldose reductase inhibitors and antioxidant agents for the treatment of diabetic complications. European Journal of Medicinal Chemistry, 2011, 46, 2797-2806.	5.5	94
9	Synthesis and Evaluation of Translocator 18 kDa Protein (TSPO) Positron Emission Tomography (PET) Radioligands with Low Binding Sensitivity to Human Single Nucleotide Polymorphism rs6971. ACS Chemical Neuroscience, 2014, 5, 963-971.	3.5	91
10	Anxiolytic-like Effects of <i>N</i> , <i>N</i> -Dialkyl-2-phenylindol-3-ylglyoxylamides by Modulation of Translocator Protein Promoting Neurosteroid Biosynthesis. Journal of Medicinal Chemistry, 2008, 51, 5798-5806.	6.4	80
11	GABAA/Bz Receptor Subtypes as Targets for Selective Drugs. Current Medicinal Chemistry, 2007, 14, 2680-2701.	2.4	76
12	N,N-Dialkyl-2-phenylindol-3-ylglyoxylamides. A New Class of Potent and Selective Ligands at the Peripheral Benzodiazepine Receptor. Journal of Medicinal Chemistry, 2004, 47, 1852-1855.	6.4	75
13	Novel Pyrazolopyrimidine Derivatives as Tyrosine Kinase Inhibitors with Antitumoral Activity in Vitro and in Vivo in Papillary Dedifferentiated Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E288-E296.	3.6	71
14	Synthesis, in vitro antiproliferative activity and DNA-interaction of benzimidazoquinazoline derivatives as potential anti-tumor agents. Il Farmaco, 2001, 56, 159-167.	0.9	70
15	Apoptosis Therapy in Cancer: The First Single-molecule Co-activating p53 and the Translocator Protein in Glioblastoma. Scientific Reports, 2014, 4, 4749.	3.3	62
16	Genetic analysis of <scp>dTSPO</scp> , an outer mitochondrial membrane protein, reveals its functions in apoptosis, longevity, and Aî²42â€induced neurodegeneration. Aging Cell, 2014, 13, 507-518.	6.7	60
17	Synthesis, DNA binding and in vitro antiproliferative activity of purinoquinazoline, pyridopyrimidopurine and pyridopyrimidobenzimidazole derivatives as potential antitumor agents. European Journal of Medicinal Chemistry, 1998, 33, 685-696.	5.5	57
18	3-Aryl[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-ones:Â A New Class of Selective A1Adenosine Receptor Antagonists. Journal of Medicinal Chemistry, 2001, 44, 316-327.	6.4	56

#	Article	IF	CITATIONS
19	Synthesis, Structureâ^'Activity Relationships, and Molecular Modeling Studies ofN-(Indol-3-ylglyoxylyl)benzylamine Derivatives Acting at the Benzodiazepine Receptorâ€,‡. Journal of Medicinal Chemistry, 1996, 39, 5083-5091.	6.4	54
20	Derivatives of 4-Amino-6-hydroxy-2-mercaptopyrimidine as Novel, Potent, and Selective A ₃ Adenosine Receptor Antagonists. Journal of Medicinal Chemistry, 2008, 51, 1764-1770.	6.4	54
21	Microglial Pro-Inflammatory and Anti-Inflammatory Phenotypes Are Modulated by Translocator Protein Activation. International Journal of Molecular Sciences, 2019, 20, 4467.	4.1	54
22	Naphtho[1,2-d]isothiazole Acetic Acid Derivatives as a Novel Class of Selective Aldose Reductase Inhibitors. Journal of Medicinal Chemistry, 2005, 48, 6897-6907.	6.4	53
23	TSPO ligand residence time: a new parameter to predict compound neurosteroidogenic efficacy. Scientific Reports, 2016, 6, 18164.	3.3	53
24	The Alpha Keto Amide Moiety as a Privileged Motif in Medicinal Chemistry: Current Insights and Emerging Opportunities. Journal of Medicinal Chemistry, 2021, 64, 3508-3545.	6.4	51
25	Novel <i>N</i> ² -Substituted Pyrazolo[3,4- <i>d</i>]pyrimidine Adenosine A ₃ Receptor Antagonists: Inhibition of A ₃ -Mediated Human Glioblastoma Cell Proliferation ^{â€} . Journal of Medicinal Chemistry, 2010, 53, 3954-3963.	6.4	50
26	2-(Benzimidazol-2-yl)quinoxalines:Â A Novel Class of Selective Antagonists at Human A1and A3Adenosine Receptors Designed by 3D Database Searching. Journal of Medicinal Chemistry, 2005, 48, 8253-8260.	6.4	49
27	Inhibition of metalloproteinases derived from tumours: new insights in the treatment of human glioblastoma. Neuroscience, 2010, 168, 514-522.	2.3	49
28	CLM94, a Novel Cyclic Amide with Anti-VEGFR-2 and Antiangiogenic Properties, Is Active against Primary Anaplastic Thyroid Cancer in Vitro and in Vivo. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E528-E536.	3.6	49
29	Iminothioethers as Hydrogen Sulfide Donors: From the Gasotransmitter Release to the Vascular Effects. Journal of Medicinal Chemistry, 2017, 60, 7512-7523.	6.4	48
30	Indole amide derivatives: synthesis, structure–activity relationships and molecular modelling studies of a new series of histamine H1-receptor antagonists. European Journal of Medicinal Chemistry, 1999, 34, 93-105.	5.5	47
31	Novel, Highly Potent Adenosine Deaminase Inhibitors Containing the Pyrazolo[3,4-d]pyrimidine Ring System. Synthesis, Structureâ ´Activity Relationships, and Molecular Modeling Studies. Journal of Medicinal Chemistry, 2005, 48, 5162-5174.	6.4	47
32	Acetic Acid Aldose Reductase Inhibitors Bearing a Five-Membered Heterocyclic Core with Potent Topical Activity in a Visual Impairment Rat Model. Journal of Medicinal Chemistry, 2008, 51, 3182-3193.	6.4	47
33	The Blockade of Adenosine Deaminase Ameliorates Chronic Experimental Colitis through the Recruitment of Adenosine A _{2A} and A ₃ Receptors. Journal of Pharmacology and Experimental Therapeutics, 2010, 335, 434-442.	2.5	47
34	New Fluorescent 2-Phenylindolglyoxylamide Derivatives as Probes Targeting the Peripheral-Type Benzodiazepine Receptor:Â Design, Synthesis, and Biological Evaluation. Journal of Medicinal Chemistry, 2007, 50, 404-407.	6.4	46
35	Design, synthesis and biological evaluation of new classes of thieno[3,2-d]pyrimidinone and thieno[1,2,3]triazine as inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2). European Journal of Medicinal Chemistry, 2013, 63, 765-781.	5.5	46
36	CLM3, a Multitarget Tyrosine Kinase Inhibitor With Antiangiogenic Properties, Is Active Against Primary Anaplastic Thyroid Cancer In Vitro and In Vivo. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E572-E581.	3.6	46

#	Article	IF	CITATIONS
37	Hydrogen Sulphide: Biopharmacological Roles in the Cardiovascular System and Pharmaceutical Perspectives. Current Medicinal Chemistry, 2012, 19, 3325-3336.	2.4	45
38	Exploiting the Pyrazolo[3,4-d]pyrimidin-4-one Ring System as a Useful Template To Obtain Potent Adenosine Deaminase Inhibitors. Journal of Medicinal Chemistry, 2009, 52, 1681-1692.	6.4	44
39	Phenylpyrazolo[1,5- <i>a</i>]quinazolin-5(4 <i>H</i>)-one: A Suitable Scaffold for the Development of Noncamptothecin Topoisomerase I (Top1) Inhibitors. Journal of Medicinal Chemistry, 2013, 56, 7458-7462.	6.4	43
40	Progresses in the pursuit of aldose reductase inhibitors: The structure-based lead optimization step. European Journal of Medicinal Chemistry, 2012, 51, 216-226.	5.5	41
41	Structure–Activity Relationship Refinement and Further Assessment of 4-Phenylquinazoline-2-carboxamide Translocator Protein Ligands as Antiproliferative Agents in Human Glioblastoma Tumors. Journal of Medicinal Chemistry, 2014, 57, 2413-2428.	6.4	41
42	[1,2,4]Triazino[4,3-a]benzimidazole Acetic Acid Derivatives:Â A New Class of Selective Aldose Reductase Inhibitors. Journal of Medicinal Chemistry, 2001, 44, 4359-4369.	6.4	40
43	Anxiolytic properties of a 2-phenylindolglyoxylamide TSPO ligand: Stimulation of in vitro neurosteroid production affecting GABAA receptor activity. Psychoneuroendocrinology, 2011, 36, 463-472.	2.7	40
44	Novel, Highly Potent Aldose Reductase Inhibitors:  Cyano(2-oxo-2,3-dihydroindol-3-yl)acetic Acid Derivatives. Journal of Medicinal Chemistry, 2003, 46, 1419-1428.	6.4	39
45	Structural Requirements to Obtain Highly Potent and Selective 18 kDa Translocator Protein (TSPO) Ligands. Current Topics in Medicinal Chemistry, 2011, 11, 860-886.	2.1	39
46	A New Approach to Control the Enigmatic Activity of Aldose Reductase. PLoS ONE, 2013, 8, e74076.	2.5	39
47	Translocator Protein Ligands as Promising Therapeutic Tools for Anxiety Disorders. Current Medicinal Chemistry, 2009, 16, 3359-3380.	2.4	38
48	Arylsulfonamide inhibitors of aggrecanases as potential therapeutic agents for osteoarthritis: Synthesis and biological evaluation. European Journal of Medicinal Chemistry, 2013, 62, 379-394.	5.5	38
49	NovelN-(Arylalkyl)indol-3-ylglyoxylylamides Targeted as Ligands of the Benzodiazepine Receptor:Â Synthesis, Biological Evaluation, and Molecular Modeling Analysis of the Structureâ^'Activity Relationshipsâ€. Journal of Medicinal Chemistry, 2001, 44, 2286-2297.	6.4	36
50	Pursuing Aldose Reductase Inhibitors through in Situ Cross-Docking and Similarity-Based Virtual Screening. Journal of Medicinal Chemistry, 2009, 52, 5578-5581.	6.4	36
51	Synthesis and biological evaluation in U87MG glioma cells of (ethynylthiophene)sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors. European Journal of Medicinal Chemistry, 2011, 46, 2617-2629.	5.5	36
52	Synthesis and Biological Evaluation of 4-Phenylquinazoline-2-carboxamides Designed as a Novel Class of Potent Ligands of the Translocator Protein. Journal of Medicinal Chemistry, 2012, 55, 4506-4510.	6.4	36
53	TSPO-ligands prevent oxidative damage and inflammatory response in C6 glioma cells by neurosteroid synthesis. European Journal of Pharmaceutical Sciences, 2016, 88, 124-131.	4.0	36
54	Tricyclic Sulfonamides Incorporating Benzothiopyrano[4,3-c]pyrazole and Pyridothiopyrano[4,3-c]pyrazole Effectively Inhibit α- and β-Carbonic Anhydrase: X-ray Crystallography and Solution Investigations on 15 Isoforms. Journal of Medicinal Chemistry, 2012, 55, 9619-9629.	6.4	35

#	Article	IF	CITATIONS
55	Spirohydantoin derivatives of thiopyrano[2,3-b]pyridin-4(4H)-one as potent in vitro and in vivo aldose reductase inhibitors. Bioorganic and Medicinal Chemistry, 2005, 13, 491-499.	3.0	34
56	Computational Studies of Epidermal Growth Factor Receptor: Docking Reliability, Three-Dimensional Quantitative Structureâ^'Activity Relationship Analysis, and Virtual Screening Studies. Journal of Medicinal Chemistry, 2009, 52, 964-975.	6.4	34
57	p53 Functional Inhibitors Behaving Like Pifithrin-β Counteract the Alzheimer Peptide Non-β-amyloid Component Effects in Human SH-SY5Y Cells. ACS Chemical Neuroscience, 2014, 5, 390-399.	3.5	34
58	Osteoblast differentiation and survival: A role for A2B adenosine receptor allosteric modulators. Biochimica Et Biophysica Acta - Molecular Cell Research, 2014, 1843, 2957-2966.	4.1	34
59	The Anxiolytic Etifoxine Binds to TSPO Ro5-4864 Binding Site with Long Residence Time Showing a High Neurosteroidogenic Activity. ACS Chemical Neuroscience, 2017, 8, 1448-1454.	3.5	33
60	Targeting the 18-kDa translocator protein: recent perspectives for neuroprotection. Biochemical Society Transactions, 2015, 43, 559-565.	3.4	32
61	TSPO PIGA Ligands Promote Neurosteroidogenesis and Human Astrocyte Well-Being. International Journal of Molecular Sciences, 2016, 17, 1028.	4.1	32
62	Deepening the Topology of the Translocator Protein Binding Site by Novel <i>N</i> , <i>N</i> -Dialkyl-2-arylindol-3-ylglyoxylamides. Journal of Medicinal Chemistry, 2015, 58, 6081-6092.	6.4	31
63	Multiple Topoisomerase I (Topol), Topoisomerase II (Topoll) and Tyrosyl-DNA Phosphodiesterase (TDP) inhibitors in the development of anticancer drugs. European Journal of Pharmaceutical Sciences, 2021, 156, 105594.	4.0	31
64	An update into the medicinal chemistry of translocator protein (TSPO) ligands. European Journal of Medicinal Chemistry, 2021, 209, 112924.	5.5	31
65	Benzothiopyranoindole-Based Antiproliferative Agents: Synthesis, Cytotoxicity, Nucleic Acids Interaction, and Topoisomerases Inhibition Properties. Journal of Medicinal Chemistry, 2009, 52, 5429-5441.	6.4	30
66	Benzodiazepine receptor affinity and interaction of some N-(indol-3-ylglyoxylyl)amine derivatives. Journal of Medicinal Chemistry, 1992, 35, 2214-2220.	6.4	28
67	3-Aryl-[1,2,4]triazino[4,3- <i>a</i>]benzimidazol-4(10 <i>H</i>)-one: A Novel Template for the Design of Highly Selective A _{2B} Adenosine Receptor Antagonists. Journal of Medicinal Chemistry, 2012, 55, 1490-1499.	6.4	28
68	Modulation of A2B adenosine receptor by 1-Benzyl-3-ketoindole derivatives. European Journal of Medicinal Chemistry, 2013, 69, 331-337.	5.5	28
69	Lead Optimization of 2-Phenylindolylglyoxylyldipeptide Murine Double Minute (MDM)2/Translocator Protein (TSPO) Dual Inhibitors for the Treatment of Gliomas. Journal of Medicinal Chemistry, 2016, 59, 4526-4538.	6.4	28
70	Novel 2-substituted-benzimidazole-6-sulfonamides as carbonic anhydrase inhibitors: synthesis, biological evaluation against isoforms I, II, IX and XII and molecular docking studies. Journal of Enzyme Inhibition and Medicinal Chemistry, 2019, 34, 1697-1710.	5.2	28
71	Two mixed valence diruthenium(<scp>ii</scp> , <scp>iii</scp>) isomeric complexes show different anticancer properties. Dalton Transactions, 2021, 50, 9643-9647.	3.3	28
72	Design, Synthesis and Biological Evaluation of NovelN-Alkyl- andN-Acyl-(7-substituted-2-phenylimidazo[1,2-a][1,3,5]triazin-4-yl)amines (ITAs) as Novel A1Adenosine Receptor Antagonists. Journal of Medicinal Chemistry, 2002, 45, 5030-5036.	6.4	27

#	Article	IF	CITATIONS
73	Identification of Anxiolytic/Nonsedative Agents among Indol-3-ylglyoxylamides Acting as Functionally Selective Agonists at the γ-Aminobutyric Acid-A (GABA _A) α ₂ Benzodiazepine Receptor. Journal of Medicinal Chemistry, 2009, 52, 3723-3734.	6.4	27
74	Non-Nucleoside Inhibitors of Human Adenosine Kinase: Synthesis, Molecular Modeling, and Biological Studies. Journal of Medicinal Chemistry, 2011, 54, 1401-1420.	6.4	27
75	Allosteric modulators of human A2B adenosine receptor. Biochimica Et Biophysica Acta - General Subjects, 2014, 1840, 1194-1203.	2.4	27
76	Antiproliferative and proapoptotic activity of CLM3, a novel multiple tyrosine kinase inhibitor, alone and in combination with SN-38 on endothelial and cancer cells. Biochemical Pharmacology, 2011, 81, 1309-1316.	4.4	26
77	Dialkylaminoalkylindolonaphthyridines as potential antitumour agents: synthesis, cytotoxicity and DNA binding properties. European Journal of Medicinal Chemistry, 2002, 37, 475-486.	5.5	25
78	Novel Irreversible Fluorescent Probes Targeting the 18 kDa Translocator Protein: Synthesis and Biological Characterization. Journal of Medicinal Chemistry, 2010, 53, 4085-4093.	6.4	25
79	Evaluation of Novel <i>N</i> ¹ -Methyl-2-phenylindol-3-ylglyoxylamides as a New Chemotype of 18 kDa Translocator Protein-Selective Ligand Suitable for the Development of Positron Emission Tomography Radioligands. Journal of Medicinal Chemistry, 2011, 54, 366-373.	6.4	25
80	Identification of novel molecular scaffolds for the design of MMP-13 inhibitors: A first round of lead optimization. European Journal of Medicinal Chemistry, 2012, 47, 143-152.	5.5	25
81	A mixed-valence diruthenium(ii,iii) complex endowed with high stability: from experimental evidence to theoretical interpretation. Dalton Transactions, 2020, 49, 14520-14527.	3.3	25
82	3-Aryl-[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-ones:Â Tricyclic Heteroaromatic Derivatives as a New Class of Benzodiazepine Receptor Ligands. Journal of Medicinal Chemistry, 2000, 43, 96-102.	6.4	24
83	Benzofuroxane Derivatives as Multi-Effective Agents for the Treatment of Cardiovascular Diabetic Complications. Synthesis, Functional Evaluation, and Molecular Modeling Studies. Journal of Medicinal Chemistry, 2012, 55, 10523-10531.	6.4	24
84	An approach to novel fused triazole or tetrazole derivatives starting from benzimidazo[1,2â€ <i>a</i>]quinazolineâ€5(7 <i>H</i>)â€one and 5,7â€dihydroâ€5â€oxopyrido[3′,2′:5,6]pyrimido[1,2â€ <i>a</i>]benzimidazole. Journal of Heterocyclic Cher 2002, 39, 1007-1011.	nistry,	23
85	Refinement of the Benzodiazepine Receptor Site Topology by Structureâ^'Activity Relationships of NewN-(Heteroarylmethyl)indol-3-ylglyoxylamides. Journal of Medicinal Chemistry, 2006, 49, 2489-2495.	6.4	22
86	5-Amino-2-phenyl[1,2,3]triazolo[1,2-a][1,2,4]benzotriazin-1-one:  A Versatile Scaffold To Obtain Potent and Selective A3 Adenosine Receptor Antagonists. Journal of Medicinal Chemistry, 2007, 50, 5676-5684.	6.4	22
87	TSPO ligand residence time influences human glioblastoma multiforme cell death/life balance. Apoptosis: an International Journal on Programmed Cell Death, 2015, 20, 383-398.	4.9	22
88	Bax Activation Blocks Self-Renewal and Induces Apoptosis of Human Glioblastoma Stem Cells. ACS Chemical Neuroscience, 2018, 9, 85-99.	3.5	22
89	Simultaneous Targeting of RCD-Integrins and Dual Murine Double Minute Proteins in Glioblastoma Multiforme. Journal of Medicinal Chemistry, 2018, 61, 4791-4809.	6.4	22
90	Unbinding of Translocator Protein 18 kDa (TSPO) Ligands: From in Vitro Residence Time to in Vivo Efficacy via in Silico Simulations. ACS Chemical Neuroscience, 2019, 10, 3805-3814.	3.5	22

#	Article	IF	CITATIONS
91	Nâ€~-Phenylindol-3-ylglyoxylohydrazide Derivatives: Synthesis, Structureâ^'Activity Relationships, Molecular Modeling Studies, and Pharmacological Action on Brain Benzodiazepine Receptors. Journal of Medicinal Chemistry, 1998, 41, 3821-3830.	6.4	21
92	Synthesis of novel 5 <i>H</i> , 11 <i>H</i> â€pyrido[2′,3′:2,3]thiopyrano[4,3â€ <i>b</i>]â€indoles by fischerâ cyclization. Journal of Heterocyclic Chemistry, 2000, 37, 379-382.	€indole 2.6	21
93	PIGA (N,N-Di-n-butyl-5-chloro-2-(4-chlorophenyl)indol-3-ylglyoxylamide), a New Mitochondrial Benzodiazepine-Receptor Ligand, Induces Apoptosis in C6 glioma Cells. ChemBioChem, 2005, 6, 1082-1088.	2.6	21
94	Novel N-Substituted Indol-3-ylglyoxylamides Probing the LDiand L1/L2Lipophilic Regions of the Benzodiazepine Receptor Site in Search for Subtype-Selective Ligandsâ€. Journal of Medicinal Chemistry, 2007, 50, 1627-1634.	6.4	21
95	Synthesis and Biological Evaluation of 2′â€Oxoâ€2,3â€dihydroâ€3′ <i>H</i> ― spiro[chromeneâ€4,5′â€{1,3]oxazolidin]â€3′yl]acetic Acid Derivatives as Aldose Reductase Inhibitors. Archiv Der Pharmazie, 2011, 344, 372-385.	V4 . 1	21
96	CLM29, a multi-target pyrazolopyrimidine derivative, has anti-neoplastic activity in medullary thyroid cancer in vitro and in vivo. Molecular and Cellular Endocrinology, 2014, 393, 56-64.	3.2	21
97	A1 adenosine receptor antagonists, 3-aryl[1,2,4]triazino[4,3-a]benzimidazol-4-(10H)-ones (ATBIs) andN-alkyl andN-acyl-(7-substituted-2-phenylimidazo[1,2-a][1,3,5]triazin-4-yl)amines (ITAs): Different recognition of bovine and human binding sites. Drug Development Research, 2004, 63, 1-7.	2.9	20
98	1,2-Benzisothiazole Derivatives Bearing 4-, 5-, or 6-Alkyl/arylcarboxamide Moieties Inhibit Carbonic Anhydrase Isoform IX (CAIX) and Cell Proliferation under Hypoxic Conditions. Journal of Medicinal Chemistry, 2016, 59, 6547-6552.	6.4	20
99	Synthesis of novel pyrido[3′,2′:5,6]thiopyrano[3,2-b]indol-5(6H)-ones and 6H-pyrido[3′,2′:5,6]thiopyrano[4,3-b]quinolines, two new heterocyclic ring systems. Journal of Heterocyclic Chemistry, 2002, 39, 1001-1006.	2.6	19
100	Computer-Aided Identification and Lead Optimization of Dual Murine Double Minute 2 and 4 Binders: Structure–Activity Relationship Studies and Pharmacological Activity. Journal of Medicinal Chemistry, 2017, 60, 8115-8130.	6.4	19
101	Specific inhibition of benzodiazepine receptor binding by some N-(indol-3-ylglyoxylyl) amino acid derivatives: stereoselective interactions. Journal of Medicinal Chemistry, 1989, 32, 2514-2518.	6.4	18
102	A novel 2,3-diphenyl-4H-pyrido[1,2-a]pyrimidin-4-one derivative inhibits endothelial cell dysfunction and smooth muscle cell proliferation/activation. European Journal of Medicinal Chemistry, 2014, 72, 102-109.	5.5	18
103	Structure-Based Optimization of Tyrosine Kinase Inhibitor CLM3 . Design, Synthesis, Functional Evaluation, and Molecular Modeling Studies Journal of Medicinal Chemistry, 2014, 57, 1225-1235.	6.4	18
104	Sulfonamides incorporating heteropolycyclic scaffolds show potent inhibitory action against carbonic anhydrase isoforms I, II, IX and XII. Bioorganic and Medicinal Chemistry, 2016, 24, 921-927.	3.0	18
105	4-Substituted Benzenesulfonamides Incorporating Bi/Tricyclic Moieties Act as Potent and Isoform-Selective Carbonic Anhydrase II/IX Inhibitors. Journal of Medicinal Chemistry, 2018, 61, 5765-5770.	6.4	18
106	Antineoplastic activity of the multitarget tyrosine kinase inhibitors CLM3 and CLM94 in medullary thyroid cancer inÂvitro. Surgery, 2014, 156, 1167-1176.	1.9	17
107	Investigation of new 2-aryl substituted Benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors targeting vascular endothelial growth factor receptor 2. European Journal of Medicinal Chemistry, 2015, 103, 29-43.	5.5	17
108	Long lasting MDM2/Translocator protein modulator: a new strategy for irreversible apoptosis of human glioblastoma cells. Oncotarget, 2016, 7, 7866-7884.	1.8	17

#	Article	IF	CITATIONS
109	Carbonic Anhydrase Activators for Neurodegeneration: An Overview. Molecules, 2022, 27, 2544.	3.8	17
110	Metal catalysis in organic reactions. 17. A nickel-promoted route to substituted allenes by reaction of 1-bromo-1,2-dienes with alkyl metals Tetrahedron Letters, 1985, 26, 5101-5104.	1.4	16
111	Synthesis of purinobenzothiazine and pyridothiazinopurine derivatives. Two new heterocyclic ring systems. Journal of Heterocyclic Chemistry, 1998, 35, 57-60.	2.6	16
112	Derivatives of Benzimidazolâ€2â€ylquinoline and Benzimidazolâ€2â€ylisoquinoline as Selective A ₁ Adenosine Receptor Antagonists with Stimulant Activity on Human Colon Motility. ChemMedChem, 2011, 6, 1909-1918.	3.2	16
113	Revisiting a Receptor-Based Pharmacophore Hypothesis for Human A _{2A} Adenosine Receptor Antagonists. Journal of Chemical Information and Modeling, 2013, 53, 1620-1637.	5.4	16
114	Acid Derivatives of Pyrazolo[1,5-a]pyrimidine as Aldose Reductase Differential Inhibitors. Cell Chemical Biology, 2018, 25, 1414-1418.e3.	5.2	16
115	Exploiting the Indole Scaffold to Design Compounds Binding to Different Pharmacological Targets. Molecules, 2020, 25, 2331.	3.8	16
116	Tertiary amides with a five-membered heteroaromatic ring as new probes for the translocator protein. European Journal of Medicinal Chemistry, 2011, 46, 4506-4520.	5.5	15
117	Synthetic analogues of flavonoids with improved activity against platelet activation and aggregation as novel prototypes of food supplements. Food Chemistry, 2015, 175, 494-499.	8.2	15
118	Targeting the KRAS oncogene: Synthesis, physicochemical and biological evaluation of novel G-Quadruplex DNA binders. European Journal of Pharmaceutical Sciences, 2020, 149, 105337.	4.0	15
119	De novo Neurosteroidogenesis in Human Microglia: Involvement of the 18 kDa Translocator Protein. International Journal of Molecular Sciences, 2021, 22, 3115.	4.1	15
120	Synthesis and Screening in Mice of Fluorine-Containing PET Radioligands for TSPO: Discovery of a Promising ¹⁸ F-Labeled Ligand. Journal of Medicinal Chemistry, 2021, 64, 16731-16745.	6.4	15
121	Synthesis of novel 1,4-dihydropyrido[3′,2′:5,6]thiopyrano[4,3-c]-pyrazoles and 5H-pyrido[3′,2′:5,6]thiopyrano[4,3-d]pyrimidines as potential antiproliferative agents. Journal of Heterocyclic Chemistry, 2003, 40, 783-788.	2.6	14
122	Synthesis andin vitroantiproliferative activity of new substituted benzo[3′,2′:5,6]thiopyrano[4,3-d]pyrimidines. Journal of Heterocyclic Chemistry, 2008, 45, 745-749.	2.6	14
123	Long Residence Time at the Neurosteroidogenic 18 kDa Translocator Protein Characterizes the Anxiolytic Ligand XBD173. ACS Chemical Neuroscience, 2016, 7, 1041-1046.	3.5	13
124	Enantiomeric 4â€Acylaminoâ€6â€alkyloxyâ€2 Alkylthiopyrimidines As Potential A ₃ Adenosine Receptor Antagonists: HPLC Chiral Resolution and Absolute Configuration Assignment by a Full Set of Chiroptical Spectroscopy. Chirality, 2016, 28, 434-440.	2.6	13
125	Exploiting the 4-Phenylquinazoline Scaffold for the Development of High Affinity Fluorescent Probes for the Translocator Protein (TSPO). Journal of Medicinal Chemistry, 2017, 60, 7897-7909.	6.4	13
126	Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors. European Journal of Medicinal Chemistry, 2018, 150, 491-505.	5.5	13

#	Article	IF	CITATIONS
127	Metal catalysis in norganic reactions. 18. Stereochemistry of the transition-metal catalyzed cross-coupling of (S)-1-bromo-3-methyl-1,2-pentadiene with isobutylmetal compounds. Tetrahedron Letters, 1986, 27, 1067-1068.	1.4	12
128	CLM29 and CLM24, pyrazolopyrimidine derivatives, have antitumoral activity in vitro in anaplastic thyroid cancer, with or without BRAF mutation. Endocrine, 2016, 53, 136-144.	2.3	12
129	Novel positive allosteric modulators of A _{2B} adenosine receptor acting as bone mineralisation promoters. Journal of Enzyme Inhibition and Medicinal Chemistry, 2021, 36, 287-295.	5.2	12
130	A3 Receptor Ligands: Past, Present and Future Trends. Current Topics in Medicinal Chemistry, 2010, 10, 942-975.	2.1	11
131	Soyasaponins from Zolfino bean as aldose reductase differential inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2019, 34, 350-360.	5.2	11
132	Synthesis of fused purinoquinazolines. Three new heterocyclic ring systems. Journal of Heterocyclic Chemistry, 1995, 32, 941-945.	2.6	10
133	Allosteric Modulators for Adenosine Receptors: An Alternative to the Orthosteric Ligands. Current Topics in Medicinal Chemistry, 2010, 10, 976-992.	2.1	10
134	Toward PET imaging of A2B adenosine receptors: a carbon-11 labeled triazinobenzimidazole tracer. Nuclear Medicine and Biology, 2016, 43, 309-317.	0.6	10
135	Long lasting inhibition of Mdm2-p53 interaction potentiates mesenchymal stem cell differentiation into osteoblasts. Biochimica Et Biophysica Acta - Molecular Cell Research, 2019, 1866, 737-749.	4.1	10
136	High Affinity Central Benzodiazepine Receptor Ligands:Â Synthesis and Biological Evaluation of a Series of Phenyltriazolobenzotriazindione Derivatives. Journal of Medicinal Chemistry, 2005, 48, 2936-2943.	6.4	9
137	Residence Time, a New parameter to Predict Neurosteroidogenic Efficacy of Translocator Protein (TSPO) Ligands: the Case Study of <i>N</i> , <i>N</i> â€Dialkylâ€2â€arylindolâ€3â€ylglyoxylamides. ChemMedChe 2017, 12, 1275-1278.	2 13, 2	9
138	Inhibition studies on carbonic anhydrase isoforms I, II, IV and IX with N-arylsubstituted secondary sulfonamides featuring a bicyclic tetrahydroindazole scaffold. European Journal of Medicinal Chemistry, 2021, 220, 113490.	5.5	9
139	Essential Principles and Recent Progress in the Development of TSPO PET Ligands for Neuroinflammation Imaging. Current Medicinal Chemistry, 2022, 29, 4862-4890.	2.4	9
140	Synthesis of purinobenzodiazepine and purinobenzotriazocine derivatives, two new heterocyclic ring systems. Journal of Heterocyclic Chemistry, 1999, 36, 639-642.	2.6	8
141	Medicinal Chemistry of Indolylglyoxylamide GABAA/BzR High Affinity Ligands: Identification of Novel Anxiolytic/Non Sedative Agents. Current Topics in Medicinal Chemistry, 2012, 12, 286-311.	2.1	8
142	Geometrically Constrained Analogues of N-Benzylindolylglyoxylylamides: [1, 2, 4]Triazino[4, 3-a]benzimidazol-4(10H)-one Derivatives as Potential New Ligands at the Benzodiazepine Receptor. Archiv Der Pharmazie, 2003, 336, 413-421.	4.1	7
143	A Virtual Screening Study of the 18 kDa Translocator Protein using Pharmacophore Models Combined with 3Dâ€QSAR Studies. ChemMedChem, 2009, 4, 1686-1694.	3.2	7
144	3-(Fur-2-yl)-10-(2-phenylethyl)-[1,2,4]triazino[4,3- <i>a</i>]benzimidazol-4(10 <i>H</i>)-one, a Novel Adenosine Receptor Antagonist with A _{2A} -Mediated Neuroprotective Effects. ACS Chemical Neuroscience, 2011, 2, 526-535.	3.5	7

#	Article	IF	CITATIONS
145	Receptor Tyrosine Kinase Kit and Gastrointestinal Stromal Tumours: An Overview. Current Medicinal Chemistry, 2011, 18, 2893-2903.	2.4	7
146	4-amino-6-alkyloxy-2-alkylthiopyrimidine derivatives as novel non-nucleoside agonists for the adenosine A1receptor. Chemical Biology and Drug Design, 2016, 88, 724-729.	3.2	7
147	New insights in the structure-activity relationships of 2-phenylamino-substituted benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors. European Journal of Medicinal Chemistry, 2018, 150, 446-456.	5.5	7
148	Anti-ischaemic activity of an antioxidant aldose reductase inhibitor on diabetic and non-diabetic rat hearts. Journal of Pharmacy and Pharmacology, 2010, 62, 107-113.	2.4	6
149	Medicinal Chemistry of Indolylglyoxylamide TSPO High Affinity Ligands with Anxiolytic-Like Effects. Current Topics in Medicinal Chemistry, 2012, 12, 333-351.	2.1	6
150	Novel fluorescent triazinobenzimidazole derivatives as probes for labelling human A1 and A2B adenosine receptor subtypes. Bioorganic and Medicinal Chemistry, 2018, 26, 5885-5895.	3.0	6
151	Facile synthesis of 3â€substituted [1,2,4]triazino[3,4â€ <i>f</i>]purineâ€4,6,8â€ŧrione derivatives. Journal of Heterocyclic Chemistry, 2001, 38, 607-612.	2.6	5
152	Benzothiopyranoindole- and pyridothiopyranoindole-based antiproliferative agents targeting topoisomerases. European Journal of Medicinal Chemistry, 2019, 165, 46-58.	5.5	5
153	Allosterism vs. Orthosterism: Recent Findings and Future Perspectives on A2B AR Physio-Pathological Implications. Frontiers in Pharmacology, 2021, 12, 652121.	3.5	5
154	Tetrahydroquinazole-based secondary sulphonamides as carbonic anhydrase inhibitors: synthesis, biological evaluation against isoforms I, II, IV, and IX, and computational studies. Journal of Enzyme Inhibition and Medicinal Chemistry, 2021, 36, 1874-1883.	5.2	4
155	Translocator Protein 18-kDa: a promising target to treat neuroinflammation-related degenerative diseases. Current Medicinal Chemistry, 2022, 29, .	2.4	4
156	Synthesis and Benzodiazepine Receptor Affinity of Derivatives of the New Tricyclic Heteroaromatic System Pyrido[3?,2?:5,6]thiopyrano[4,3-c]pyridazin-3(2H,5H)-one. Archiv Der Pharmazie, 2005, 338, 126-132.	4.1	3
157	Synthesis of New Heterocyclic Ring Systems via [1,3,5]Triazino[1,2-a]benzimidazole Derivatives. Journal of Heterocyclic Chemistry, 2005, 42, 1417-1422.	2.6	3
158	Discovery of Pyrido[3′,2′:5,6]thiopyrano[4,3- <i>d</i>]pyrimidine-Based Antiproliferative Multikinase Inhibitors. ACS Medicinal Chemistry Letters, 2019, 10, 457-462.	2.8	3
159	Carbonic anhydrase activation profile of indole-based derivatives. Journal of Enzyme Inhibition and Medicinal Chemistry, 2021, 36, 1783-1797.	5.2	3
160	Cancer Immunotherapy: An Overview on Small Molecules as Inhibitors of the Immune Checkpoint PD-1/PD-L1 (2015-2021). Mini-Reviews in Medicinal Chemistry, 2022, 22, .	2.4	3
161	Synthesis of a novel purineâ€containing heterocyclic ring system: 8,10â€Dimethylindolo[2′,3′:5,6][1,2,4]triazino[4,3â€ <i>f</i>]purineâ€9,11(8 <i>H</i> , 10 <i>H</i> , 13 <i>H Journal of Heterocyclic Chemistry, 2000, 37, 373-377.</i>	<⋬x)â€dio	næ.
162	Effects of newly-developed benzodiazepine ligands on noise-induced mitochondrial damage in the rat.	1.9	1

¹⁶² Annals of Anatomy, 2000, 182, 311-318.

#	Article	IF	CITATIONS
163	Geometrically Constrained Derivatives of Indolylglyoxylamides as Ligands Binding the GABAA/BzR Complex. Current Topics in Medicinal Chemistry, 2012, 12, 312-320.	2.1	1
164	Enriching the Arsenal of Pharmacological Tools against MICAL2. Molecules, 2021, 26, 7519.	3.8	1
165	A search for quantum mechanical methods suitable for the conformational analysis of models related to some inverse agonists of the benzodiazepine receptor. Molecular Engineering, 1994, 3, 365-376.	0.2	0
166	Synthesis and Benzodiazepine Receptor Affinity of Derivatives of the New Tricyclic Heteroaromatic System Pyrido[3′,2′:5,6]thiopyrano[4,3-c]pyridazin-3(2H,5H)-one ChemInform, 2005, 36, no.	0.0	0
167	Highlighting the New Advances in Drug Discovery and Development. ChemMedChem, 2008, 3, 181-184.	3.2	0
168	Structure–Activity Relationships on Purine and 2,3â€Đihydropurine Derivatives as Antitubercular Agents: a Data Mining Approach. Chemical Biology and Drug Design, 2011, 78, 718-724.	3.2	0
169	Editorial [Hot Topic:The Indolylglyoxylamide Scaffold as an Useful Tool to Obtain Anxiolytic Agents (Guest Editors: Sabrina Taliani & Federico Da Settimo)]. Current Topics in Medicinal Chemistry, 2012, 12, 236-237.	2.1	0
170	Drug Repurposing Meets DNA Independent Pathways: Targeting Alternative Substrates for Anticancer Therapy. Current Topics in Medicinal Chemistry, 2021, 21, 2767-2770.	2.1	0